News

This marks the first FDA approval of a TYK2 inhibitor specifically for this indication. The regulator granted this approval following findings from the pivotal POETYK PsA-I and POETYK

This approval applies to patients who have undergone at least one prior treatment, including a proteasome inhibitor and an immunomodulatory agent. It aims to provide a new standard

The licences sourced from Carisma Therapeutics and the University of Pennsylvania include methods and constructs specifically engineered for function within these immune cell populations. The designs complement Liberate Bio’s

CordenPharma Colorado will occupy the entire premises under a 15-year lease. The new LEED Gold-certified facility has flexible laboratory configurations, advanced mechanical and utility systems, and waste management

AFTX-201 is being evaluated as a one-time intravenous gene therapy in adults with genetically confirmed BAG3 DCM. The therapy delivers a fully human, full-length BAG3 transgene using the

Alprazolam is the active pharmaceutical ingredient (API) in Xanax, a commonly prescribed anti-anxiety medication. Traditional oral alprazolam tablets can require 25 minutes or more to take effect, as

Enbumyst is approved by the US Food and Drug Administration (FDA) for treating oedema linked to congestive heart failure, hepatic, and renal diseases in adults. The agreement will

Following completion, the combined entity will operate as Candid Therapeutics and list on Nasdaq under the “CDRX” ticker symbol. As part of the merger, Candid has secured more

CL-273 is a reversible, investigational, wild-type-sparing pan epidermal growth factor receptor (EGFR) small molecule inhibitor developed using an AI-based drug discovery platform. The asset specifically targets resistant mutations